CASC


Why Cascadian Therapeutics Inc (USA) Is Today’s Best Biotech Stock

Shares of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) surged as much as 72% after agreeing to be acquired by Seattle Genetics, Inc. (NASDAQ:SGEN) for $10 …

Here’s Why Cascadian Therapeutics Inc (USA) (CASC) Shares Tumble 11%

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock and Series E convertible preferred …

Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces 2017 Outlook and Recent Drug Portfolio Progress

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced an overview of recent progress for its investigational drug portfolio in addition to several anticipated key objectives …

Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Appoints Dr. Marc L. Lesnick as Senior Vice President of Regulatory Affairs and Quality

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced the appointment of Marc L. Lesnick, Ph.

Cowen Dives in on Cascadian Therapeutics Inc (USA) (CASC) Following HER2CLIMB Study Amendment

Cowen analyst Boris Peaker weighed in on Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) with a few insights after the company announced that following a recent meeting with …

Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that following a recent meeting with the U.S.

Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast Cancer

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced the presentation of clinical activity of tucatinib, its investigational, highly selective small molecule HER2 inhibitor, in combination therapy …

Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces Proposal for Reverse Stock Split

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that its board of directors has approved a plan for a reverse split of the Company’s common stock …

Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces Approval of Nonproprietary Name “tucatinib” for ONT-380

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC), a clinical-stage biopharmaceutical company, announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names (INN) …

Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer

Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts